Childhood cancer is considered rare, corresponding to~ 3% of all malignant neoplasms in
the human population. The World Health Organization (WHO) reports a universal …

Outcome in treatment of childhood cancers has improved dramatically since the 1970s. This
success was largely achieved by the implementation of cooperative clinical research trial …

The development of targeted drugs in paediatric oncology has been notoriously slow, in part
due to the peculiarities of this rare and highly heterogeneous population. To provide …

The use of targeted small-molecule therapeutics and immunotherapeutics has been limited
to date in pediatric oncology. Recently, the number of pediatric approvals has risen, and …

Introduction: Cancer is a leading cause of death in childhood. Encouraging progress has
been made in the treatment of childhood malignancies, but there is an unmet need for new …

Survival of children with cancers has dramatically improved over the past several decades.
This success has been achieved through improvement of combined modalities in treatment …

Novel drugs and treatment modalities are urgently needed to further improve survival of
children with cancer. In medical oncology, an increased understanding of the molecular …

As the mitogen-activated protein kinase (MAPK) signalling pathway is activated in many
paediatric cancers, it is an important therapeutic target. Currently, a range of targeted MAPK …

The Research to Accelerate Cures and Equity (RACE) for Children Act requires an
assessment of molecular targets relevant to pediatric cancer. Due to the biological …

In a perfect world there would be no cancer. Fantasy? Definitely, at least in the foreseeable
future. The next best thing to no cancer would be cancer therapy that is so effective and …